“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.
Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Alexander Stein(Universität Hamburg), Benjamin Garlipp(University Hospital Magdeburg), Jörg Steighardt, Fabian Maximilian Meinert(Charité - Universitätsmedizin Berlin), Thomas Goehler(Onkozentrum Dresden), Heinz‐Gert Hoeffkes(Klinikum Fulda), Malte Leithäuser(University of Rostock), Thomas Edelmann(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Arndt Vogel(Princess Margaret Cancer Centre), Helmut Forstbauer, Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Carla Hannig(Praxis für Hämatologie und Onkologie), Christian Junghanß(University of Rostock), Jörn Rüssel(Martin Luther University Halle-Wittenberg), Michael Schaefers(Praxis für Hämatologie und Onkologie), Franziska Cygon(University Hospital in Halle), Axel Florschütz(Städtisches Klinikum Dessau), Bert Hildebrandt(Charité - Universitätsmedizin Berlin)
Cited by 19
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k